Gujarat Themis Biosyn Ltd releases 25.45 lakh pledged shares held by Pharmaceutical Business Group

What Gujarat Themis Biosyn Ltd announced

Gujarat Themis Biosyn Ltd (the "Target Company") filed a revised disclosure with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on 20 July 2026. The filing confirms that its promoter, Pharmaceutical Business Group (India) Limited (the "Promoter"), released a pledge on 25.45 lakh equity shares of the Target Company on 8 July 2026. The release clears all previously recorded encumbrances on the Target’s share capital.

Details of the pledge release

The promoter’s total shareholding in Gujarat Themis Biosyn Ltd stands at 5.12 crore shares, representing 47.02% of the Target’s total share capital. Prior to the release, 2.34% of the Target’s equity (approximately 25.50 lakh shares) was pledged as security for a loan. The pledge was held in favour of Bajaj Finance Limited, with a nominal amount of 5,000 shares (0.004% of total capital) remaining after the release.

On 8 July 2026, the promoter repaid the loan that had triggered the pledge, resulting in the release of 25.45 lakh shares. Consequently, the post‑event holding of encumbered shares fell to zero, indicating that the Target’s equity is no longer subject to any pledge, lien, or non‑disposal undertaking from the promoter’s side.

Regulatory framework

The disclosure is made under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. These provisions require promoters and persons acting in concert (PAC) to promptly inform the stock exchanges and the target company of any creation, release, or invocation of encumbrances on shares. The filing must include details such as the number of shares affected, the percentage of total share capital, the type of encumbrance, the reason for the action, and the identity of the counter‑party.

By submitting the revised declaration, the promoter complies with the statutory obligation to keep the market informed of changes that could affect the control and financial position of the Target Company.

Key facts at a glance

Why this matters for investors

The removal of the pledge eliminates any immediate risk that the promoter’s pledged shares could be sold or transferred to satisfy a debt obligation. For shareholders, this means the promoter’s voting power and economic interest are now fully unencumbered, which can be viewed as a strengthening of the company’s governance profile. The action does not involve any issuance of new shares, so there is no dilution effect on existing shareholders. Additionally, the repayment of the loan to Bajaj Finance suggests that the promoter has settled a short‑term financing requirement, potentially improving its balance‑sheet flexibility.

Conclusion

Gujarat Themis Biosyn Ltd’s revised filing confirms that the promoter has fully released the pledged shares that were previously held as security for a loan. The post‑release position shows zero encumbered shares, satisfying the disclosure requirements under SEBI’s takeover regulations. The filing is now part of the public record, and no further action is required unless new encumbrances arise.

The promoter’s pledge release on 8 July 2026 clears all encumbrances on Gujarat Themis Biosyn Ltd’s equity, as disclosed on 20 July 2026.